Aneurysm Clinical Trial
Official title:
The Influence of Statin Treatment on Aneurysmatic Disease
The altered balance between the proteinases and their tissue inhibitors (TIMPS) is one of
the pathogenetical mechanism of the aneurysmatic connective tissue degeneration. The
increasement of protease, collagenase and elastase activity results indeed in a dramatic
drop of collagen and elastin tissue and serum levels.Matrix Metalloproteinases (MMPs) are a
group of proteolytic enzymes that along with their specific and non-specific inhibitors
modulate the extracellular matrix composition. Recent studies have suggested an interesting
role of microRNAs (miRNAs) in the regulation mechanisms of inflammation.
The aim of our study is to analyse the influence of statin treatment on aneurysmatic disease
by monitoring MMPs and miRNAs in aneurysmatic wall tissue and MMps blood levels.
The altered balance between the proteinases and their tissue inhibitors (TIMPS) is one of
the pathogenetical mechanism of the aneurysmal connective tissue degeneration. The increase
of protease, collagenase and elastase activity results indeed in a dramatic drop of collagen
and elastin tissue and serum levels.
Vessels wall strength decrease is associated with the blood flow shear stress and affects
negatively the walls integrity, causing the aneurysmatic vessel degeneration.
Matrix Metalloproteinases (MMPs) are a group of proteolytic enzymes that along with their
specific and non-specific inhibitors modulate the extracellular matrix composition.
So far, 25 MMPs have been discovered, in particular, the ones that will be considered in
this study are: MMP-2, MMP-9, and neutrophil gelatinase-associated lipocalin (NGAL) a
related protein which is able to control MMP-9 activities.
Inflammation plays a central role in the pathogenetical pathway of aneurysmatic
developement. Recent studies have suggested an interesting role of miRNAs in the regulation
mechanisms of inflammation. miRNAs are short ribonucleic acid molecules usually composed of
20 to 25 nucleotides that can regulate mRNA transcription and protein translation by
targeting the 3'-untranslated regions (3'-UTR) of target genes. miRNAs are involved in
various physiological responses and pathological processes. Increasing evidence suggest that
miRNAs are involved in inflammatory responses. In particular the ones that will be focused
on this study are: miR-29b, miR-21, miR-181a, miR-150.
Very often, patients with aneurysmatic disease are under statin treatment. Some Statins
(Atorvastatin, Simvastatin or Rosuvastatin) with pleiotropic effects may also play a
protective role by conditioning the progression of the aneurysmatic degeneration.
The aim of our study is to analyse the influence of statin treatment on aneurysmatic disease
by monitoring some MMPs and related molecules (MMP-2, MMP-9 and NGAL), miRNAs (the
evaluation will be performed in aneurysmatic wall tissues and circulating blood levels).
Patients affected by central and peripheral aneurysmatic disease will be recruited and then
divided in two groups based on the dosage of the statin treatment: the first group with
maximum statin daily dose (Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg), the
second group with minimum statin daily dose. The latter will be defined as the control
group.
Only patients which will fullfill the criteria to undergo surgical treatment will be
recruited in the study in order to collect biological specimen of the aneurysmatic tissues .
The investigation consist in:
- taking a preoperative blood sample to evaluate the MMPs circulating levels
- taking an aneurysmatic vessel wall histological sample with an intraoperative biopsy to
evaluate the tissue MMPs and miRNAs levels.
Previously, several studies suggested a role of MMPs (MMP-2 and MMP-9) and miRNAs in
regulation of aneurysm developement, in particular miR29b, miR-181a, miR-21, miR-150.
The comparison between MMPs Levels in the study group and in the control group might
highlight a role for MMPs level as a marker of aneurysmatic disease progression,
consequently allowing the patient's stratification by analysing the risk of aneurysmatic
evolution and growth.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06235619 -
Arch Size Study for Anatomical Variations
|
||
Not yet recruiting |
NCT00905931 -
Lycopene Following Aneurysmal Subarachnoid Haemorrhage
|
Phase 2 | |
Completed |
NCT01178710 -
Effect of Simvastatin on Cardiac Function
|
N/A | |
Completed |
NCT00349908 -
A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries
|
Phase 1 | |
Recruiting |
NCT03285100 -
The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation
|
N/A | |
Recruiting |
NCT06189950 -
Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE
|
N/A | |
Active, not recruiting |
NCT04592185 -
The Study of the Fenestrated Anaconda Device in the Treatment of Abdominal Aortic Aneurysms
|
||
Completed |
NCT01970605 -
Silver Graft All Comers Registry
|
||
Completed |
NCT00282893 -
Balloon Prophylaxis of Aneurysmal Vasospasm
|
Phase 2 | |
Active, not recruiting |
NCT00549380 -
Clinical Study of Aneurysm Exclusion
|
Phase 1 | |
Completed |
NCT04598802 -
COvera in BRAnch Registry
|
||
Completed |
NCT04246125 -
Patient Skin Dose in Interventional Radiology
|
||
Recruiting |
NCT05829746 -
PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM REGISTRATION TRIAL OF THE TUBRIDGE FOR THE TREATMENT OF WIDE-NECKED SMALL AND MEDIUM-SIZED INTRACRANIAL ANEURYSMS
|
N/A | |
Completed |
NCT03242343 -
VasQ External Support for Arteriovenous Fistula
|
N/A | |
Recruiting |
NCT02878967 -
Standardized Long Term Follow-up of Patients After Endovascular Embolization of a Brain Aneurysm
|
||
Active, not recruiting |
NCT02345005 -
Iliac Branch Excluder ReGistry (IceBERG)
|
||
Recruiting |
NCT02167997 -
EffectiveNess and SAfety of Small ANeurysm COiling Trial
|
N/A | |
Recruiting |
NCT00549016 -
Clinical Study of Aneurysm Exclusion
|
N/A | |
Completed |
NCT02848612 -
Evaluation of the Amiens University Hospital Neuroradiology Anticoagulation Protocol
|
||
Enrolling by invitation |
NCT04269447 -
Prospective Aortic Biobank of POP-STAR
|